Curated News
By: NewsRamp Editorial Staff
June 10, 2025
Glucotrack Innovates Diabetes Care with Implantable Glucose Monitor
TLDR
- Glucotrack Inc.'s innovative CBGM system offers a competitive edge by providing more accurate, long-term glucose monitoring without the visibility or discomfort of wearables.
- Glucotrack's CBGM system works by directly measuring blood glucose levels, eliminating inaccuracies and delays associated with interstitial fluid readings, and requires minimal maintenance for up to 3 years.
- Glucotrack's CBGM system improves diabetes management by addressing patient concerns over accuracy and discomfort, fostering trust and enhancing quality of life for individuals with diabetes.
- Glucotrack's fully implantable CBGM system marks a revolutionary step in diabetes care, offering a discreet, hassle-free solution with promising early clinical results.
Impact - Why it Matters
This news is pivotal for individuals living with diabetes, as Glucotrack's innovative approach to continuous glucose monitoring addresses the critical issues of accuracy, convenience, and emotional well-being that current systems fail to fully resolve. The development of a fully implantable CBGM system could significantly improve the quality of life for diabetes patients by offering a more reliable, less intrusive, and emotionally supportive solution. Furthermore, Glucotrack's engagement with a Patient Advisory Board ensures that the technology is developed with direct input from those it aims to help, marking a significant step forward in patient-centered healthcare innovation.
Summary
Glucotrack Inc. (NASDAQ: GCTK), a pioneer in medical device innovation, has taken a groundbreaking approach to continuous blood glucose monitoring (CBGM) by forming a Patient Advisory Board (PAB) composed of individuals living with type 1 diabetes. This initiative aims to bridge the gap between patient experiences and technological development, focusing on the shortcomings of current glucose monitoring systems such as inaccuracy, compression lows, allergic reactions, and the emotional toll on patients. Glucotrack's response is a fully implantable CBGM system designed for long-term functionality, eliminating the need for adhesives and providing direct blood glucose measurements for enhanced accuracy.
The company has made significant strides with its CBGM system, completing a first-in-human feasibility study with promising results, including a 99% data capture rate and an average MARD of 6.7%. With ethical approval for a year-long clinical study in Melbourne and participation in the 2025 American Diabetes Association (ADA) Scientific Sessions, Glucotrack is poised to redefine diabetes management. Their presence at ADA 2025 will include live presentations and a scientific poster session, showcasing the CBGM's potential to address the core issues faced by diabetes patients today.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Glucotrack Innovates Diabetes Care with Implantable Glucose Monitor
